Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More

“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.

Roche headquarters
Roche pharma CEO Teresa Graham gave her perspective on several topics • Source: Shutterstock

Roche Holding AG pharmaceuticals CEO Teresa Graham said she remains enthusiastic about the opportunity for new drugs in Alzheimer’s disease, encouraged by Roche’s late-stage pipeline across therapeutic areas, and concerned about the European innovation landscape, in one of her first appearances since assuming the leadership role.

Graham took over the top pharma role at Roche in March, succeeding Bill Anderson, who left the company last year and was appointed CEO of Bayer AG. The transition comes amid a broader leadership shakeup at Roche, with CEO Severin Schwan also stepping down this year to be succeeded by Thomas Shinecker. While Graham has had a nearly 20-year career at Roche, working most recently as head of global product strategy, she hasn’t had as high of a public profile as some industry executives do before stepping into a CEO type role, in part because of the company’s diversified business model

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from Scrip

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By 

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.